Clinical trials: Non Organic Psychosis
Psychosis
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk
Background Psychosis is a mental health condition that affects around 3 in 100 people in their lifetime. Most treatments for psychosis target a brain chemical called dopamine but they don't work for everyone and don't address…
- Trial name
- LEVHIPPRO (NCT06224530)
- Testing
- Levetiracetam
- Where
- United Kingdom
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- King's College London
First Episode Psychosis (FEP), At Risk Mental State (ARMS)
Reducing the Duration of Untreated Psychosis in the United States
The goal of this project is to investigate whether a systematic screening approach for individuals with first episode psychosis (FEP) can substantially reduce Duration of Untreated Psychosis (DUP).
- Trial name
- NCT03369730
- Where
- 3 sites in United States
- Volunteers
- 94 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Parkinson's Disease Psychosis
Expanded Access of Pimavanserin for Patients With PD Psychosis
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
- Trial name
- NCT02762591
- Testing
- Pimavanserin tartrate
- Sponsor
- ACADIA Pharmaceuticals Inc.
Psychosis, Cannabis Use
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries.
- Trial name
- NCT07001878
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
First-Episode Psychosis
Trial to Increase FEP Attendance
Individuals with first-episode psychosis (FEP) are at high-risk for several poor functional and clinical outcomes, including suicide.
- Trial name
- NCT05967195
- Testing
- Financial Incentive and Text-Messages
- Where
- 3 sites in United States
- Volunteers
- 145 people
- Sponsor
- University of Pennsylvania
Prodromal Schizophrenia
Early Detection and Intervention for Women At-risk of Psychosis
This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.
- Trial name
- NCT03751865
- Testing
- CBT, Psychoeducation
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Quality of Life
Milestones of Adjustment Post-Psychosis
This nested design clinical outcome study of psychiatric case manager education on disease state, psychopharmacology of schizophrenia, relapse, motivational interviewing, and the process of psychological adjustment post-psychosis…
- Conditions
- Schizophrenia, Quality of Life, Adjustment, Psychological, Medication Adherence
- Trial name
- MAPP (NCT01192594)
- Testing
- Training in all modules including MAPP Recovery Model, Training in all modules except MAPP Recovery Model
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Yale University
Bipolar Affective Disorder
Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder
Bipolar affective disorder or manic -depressive psychosis (MDP) is a mood disorder affecting 2.4% of the global population . Lithium is considered as the "gold standard" for the treatment of bipolar disorder but the clinical use…
- Trial name
- NCT04222816
- Testing
- Lithium Carbonate, Sodium chloride
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Psychosis
Computer-Aided Learning for Managing Stress
The purpose of this study is to learn whether a new family therapy using computer games with biofeedback might help people at clinical high risk for psychosis and their family members learn to experience less stress and have…
- Trial name
- CALMS (NCT02531243)
- Testing
- CALMS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Healthy
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
50 healthy volunteers (HV) will participate in 2 identical ketamine-induced pharmacoBOLD (phBOLD) sessions at least 7 days apart.
- Trial name
- NCT04589208
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Psychosis
Multiomic Diagnostics in Youth With Psychosis
Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic…
- Trial name
- NCT05457140
- Testing
- Genetic: Genomic sequencing and molecular diagnostic results, if any., Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rady Pediatric Genomics & Systems Medicine Institute
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce…
- Trial name
- EaSIE (NCT05509998)
- Testing
- Screening Method (SM), Screening and Communication Method (SCM)
- Where
- United States
- Volunteers
- 912 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Negative Type; Schizophrenic, Anhedonia
Motive-specific Intervention for Negative Symptoms in Schizophrenia
The aim of this study is to test a therapeutic intervention to reduce negative symptomatic among schizophrenia patients. Since the intervention can take place within an inpatient stay, it is a short intervention.
- Conditions
- Negative Type; Schizophrenic, Anhedonia, Apathy
- Trial name
- MoNSS (NCT04793438)
- Testing
- Motive-specific intervention, Supportive conversations
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Bipolar Disorder
Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder
This study will evaluate the effectiveness of interpersonal and social rhythm therapy (IPSRT) versus clinical status and symptom response therapy (CSSRT) in reinforcing the treatment of bipolar disorder in individuals who are…
- Trial name
- NCT00227968
- Testing
- Interpersonal Social Rhythm Therapy (IPSRT), Clinical Status and Symptom Response Therapy (CSSRT)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of Pittsburgh
Clinical High Risk for Psychosis (CHR)
A Multimodal Imaging Study of Dopamine in Early Psychosis
The development of new treatments for psychosis, a psychiatric condition that is prevalent and highly disabling despite antipsychotic medications, has been limited, in part, by a lack of information from brain imaging studies…
- Trial name
- MISDEP (NCT06977308)
- Testing
- Methylphenidate (MPH), [11C]raclopride
- Volunteers
- 115 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizophreniform Disorders
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
This study aims to test the hypothesis that addition of Individual Placement and Support (IPS) and/or Cognitive Remediation Therapy (CRT) in addition to treatment as usual in patients with early psychosis will be feasible and…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis
- Trial name
- NCT03974620
- Testing
- Individual Placement and Support, Cognitive Remediation Therapy
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Living and Learning
Persistent Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.
Psychotic disorders often develop a chronic course with devastating consequences for individuals, families, and societies usually with first onset during adolescence and early adulthood.
- Conditions
- Persistent Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified, Schizophrenia, Schizoaffective Disorder
- Trial name
- SEEearly (NCT05824117)
- Testing
- Individual Placement and Support (IPS)
- Where
- 6 sites in Germany
- Volunteers
- 184 people
- Sponsor
- Charite University, Berlin, Germany
First Episode Psychosis, Psychosis
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness…
- Conditions
- First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective
- Trial name
- NCT04298450
- Testing
- Active SMS Intervention
- Where
- Canada
- Volunteers
- 186 people
- Sponsor
- Centre for Addiction and Mental Health
First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.